Modulation of the A3 adenosine receptor by low agonist concentration induces antitumor and myelostimulatory effects

Drug Development Research

Volumn 58, Issue 4, 2003, Pages 386-389

  Merimsky, Ofer ^a   Bar Yehuda, Sara ^c   Madi, Lea ^b   Fishman, Pnina ^b,c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b Can Fite BioPharma Ltd   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

A3 adenosine receptor; Cancer; Chemotherapy; Myelostimulation

Indexed keywords

1 DEOXY 1 [6 [[(3 IODOPHENYL)METHYL]AMINO] 9H PURIN 9 YL] N METHYL BETA DEXTRO RIBOFURANURONAMIDE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ANTINEOPLASTIC AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N6 (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER CELL; CANCER INHIBITION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME REGULATION; INTERNALIZATION; LEUKOCYTE COUNT; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 0038050395     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10182     Document Type: Conference Paper

References (18)

1. Bar-Yehuda S, Farbstein T, Barer F, Ohana G, Fishman P. 1999. Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice. Clin Exp Metastasis 17:531-535.
2. Bar-Yehuda S, Barer F, Volfsson L, Fishman P. 2001. Resistance of muscle to tumor metastases: a role for a3 adenosine receptor agonists. Neoplasia 3:125-131.
3. Bar-Yehuda S, Madi L, Barak D, Mittelman M, Ardon E, Ochaion A, Cohn S, Fishman R 2002. Agonists to the A3 adenosine receptor induce G-CSF production via NF-κB activation: a new class of myeloprotecyive agents. Exp Hematol 30:1390-1398.
4. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC Jr, Gilbert CJ, Oette DH. 1988. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869-876.
5. Datta SR, Brunet A, Greenberg ME. 1999. Cellular survival: a play in three Akts. Genes Dev 13:2905-2927.
6. Djaldetti M, Sredni B, Zigelman R, Verber M, Fishman P. 1996. Muscle cells produce a low molecular weight factor with anticancer activity. Clin Exp Metastasis 14:189-196.
7. Dunn SM, Coles LS, Lang RK, Gerondakis S, Vadas MA, Shannon MF. 1994. Requirement for nuclear factor (NF)-kappa B p65 and NF-interleukin-6 binding elements in the tumor necrosis factor response region of the granulocyte colony-stimulating factor promoter. Blood 83:2469-2479.
8. Ferkey DM, Kimelman D. 2000. GSK-3: new thoughts on an old enzyme. Dev Biol 225:471-479.
9. Fishman P, Bar-Yehuda S, Vagman L. 1998. Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. Cancer Res 58:3181-3187.
10. Fishman P, Bar-Yehuda S, Farbstein T, Barer F, Ohana G. 2000a. Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors. J Cell Physiol 183:393-398.
11. Fishman P, Bar-Yehuda S, Ohana G, Pathak S, Wasserman L, Barer F, Multani AS. 2000b. Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor. Eur J Cancer 36:1452-1458.
12. Fishman P, Bar-Yehuda S, Barer F, Madi L, Multani AS, Pathak S. 2001. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269:230-236.
13. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, Khalili K. 2002. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 21:4060-4064.
14. Gutkind JS. 1998. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene 17:1331-1342.
15. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. 2001. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12:73-90.
16. Morin PJ. 1999. beta-Catenin signaling and cancer. Bioessays 21:1021-1030
17. Novak A, Dedhar S. 1999. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 56:523-537.
18. Ohana G, Bar-Yehuda S, Barer F, Fishman P. 2001. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol 186:19-23.